Biological determinants of cancer progression in men with prostate cancer

JAMA

Volumn 281, Issue 15, 1999, Pages 1395-1400

  Stamey, Thomas A ^a,c   McNeal, John E ^a   Yemoto, Cheryl M ^a   Sigal, Bronislava M ^b   Johnstone, Iain M ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD LAW SCHOOL   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER INVASION; DIAGNOSTIC TEST; DISEASE MARKER; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; ORGAN WEIGHT; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATECTOMY; TREATMENT FAILURE; TREATMENT PLANNING;

EID: 0033591010     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.281.15.1395     Document Type: Article

References (18)

1. Gleason DF. Histologic grading and clinical staging of carcinoma of the prostate. In: Tannenbaum M, ed. Urologic Pathology: The Prostate. Philadelphia, Pa: Lea & Febiger; 1977:171-197.
2. Villers AA, McNeal JE, Freiha FS, Stamey TA. Multiple cancers in the prostate: morphologic features of clinically recognized versus incidental tumors. Cancer. 1992;70:2313-2318.
3. McNeal JE, Villers AA, Redwine EA, Freiha FS, Stamey TA. Capsular penetration in prostate cancer: significance for natural history and treatment. Am J Surg Pathol. 1990;14:240-247.
4. McNeal JE, Yemoto CEM. Spread of adenocarcinoma within prostatic ducts and acini: morphologic and clinical correlations. Am J Surg Pathol. 1996;20: 802-814.
5. McNeal JE, Yemoto CEM. The significance of demonstrable vascular space invasion for the progression of prostatic adenocarcinoma. Am J Surg Pathol. 1996;20:1351-1360.
6. McNeal JE, Villers AA, Redwine EA, Freiha FS, Stamey TA. Histologic differentiation, cancer volume and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer. 1990;66:1225-1233.
7. McNeal JE, Cleason DF. Classification de Gleason des adenocarcinomes prostatiques. Ann Pathol. 1991; 11:263-268.
8. Prestigiacomo AF, Stamey TA. A comparison of 4 ultrasensitive prostate specific antigen assays for early detection of residual cancer after radical prostatectomy. J Urol. 1994;152:1515-1519.
9. Stamey TA. Lower limits of detection, biological detection limits, functional sensitivity or residual cancer detection limit? sensitivity reports of PSA assays mislead the clinician. Clin Chem. 1996;42:849-852.
10. Cox DR, Oakes D. Analysis of Survival Data. New York, NY: Chapman & Hall; 1984.
11. Venables WN, Ripley BD. Modern Applied Statistics With S-PLUS. 2nd ed. New York, NY: Springer-Verlag NY Inc; 1997:357.
12. Cox DR, Snell EJ. Analysis of Binary Data. 2nd ed. New York, NY: Chapman & Hall; 1989:appendix 2.
13. Mosteller F, Tukey JW. Data Analysis and Regression. Reading, Mass: Addison-Wesley Publishing Co; 1977.
14. Stamey TA, Sözen TS, Yemoto CM, McNeal JE. Classification of "localized" untreated prostate cancer based on 791 men treated only by radical prostatectomy: common ground for therapeutic trials and TNM subgroups. J Urol. 1998;159:2009-2012.
15. Stamey TA. Making the most out of six systematic sextant biopsies. Urology. 1995;45:2-12.
16. Babaian RJ, Troncoso P, Steelhammer LC, Lloreta-Trull J, Ramirez El. Tumor volume and prostate-specific antigen: implications for early detection and defining a window of curability. J Urol. 1995;154: 1808-1812.
17. Katcher J, Klein E, Kupelian P. Outcome after radiation vs surgery for stage T1-T2 prostate cancer in patients with minimum 5-year follow-up [abstract]. J Urol. 1997;157(suppl):418. Abstract 1631.
18. Isaacs JT. Molecular markers for prostate cancer metastasis. Am J Pathol. 1997;150:1511-1521.